Skip to main content

Table 1 Summary of pediatric rheumatology patient demographics, neoplasms and medications

From: Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study

Patient ID/ gender Age at diagnosis of rheumatologic disease (years) Age at diagnosis of neoplasm (years) Neoplasm Anti-TNFα (dose/Duration) Time from
Rheumatologic diagnosis to neoplasm (years)
Time from start of anti-TNFα to neoplasm (years) Concomitant and previous DMARD, cytotoxic agent and other Biologic (years) Other concomitant and previous medications Family history of malignancy
A/Female Extended oligo JIA (1.6 years) 17 Ewing’s sarcoma etanercept 25 mg biweekly × 2.6 years 16.7 5.3 methotrexate (7.2),
leflunomide (0.2)
naprosyn, prednisone, folic acid Unknown
B/Female Poly JIA (8.2 years) 24 renal clear cell carcinoma etanercept 25 mg weekly ×  4.8 years,
infliximab 400 mg x one dose
15.8 10.6
from etanercept,
4.4 from infliximab
rituximaba (2 doses),
methotrexate (6.2),
leflunomide (0.2), sulfasalazine (0.9), azathioprine (1.2), cyclosporine A (1.5)
naprosyn, prednisone, hydroxychloroquine, amitriptyline, oxycodone, depo-provera, folic acid Unknown
C/Female Extended oligo JIA with anterior uveitis (2.0 years) 14 benign pilo-matricoma infliximab 200–500 mg monthly ×  0.25 years 12.7 1.3 cyclosporine A (3.2), azathioprine (4.3),
methotrexate (6.0), leflunomide (2.8)
hydroxychloroquine,
acetazolamide,
alendronate,
iron, calcium
Multiple family members with colon cancer
D/Male Idiopathic uveitis
(10.8 years)
16 naso-pharyngeal cancer infliximab 300–400 mg monthly ×  3.3 years 5.3 3.3 methotrexate (4.7) folic acid Maternal grandfather with lung cancer; Maternal grandmother with cervical cancer
E/Female Systemic JIA (4.7years) 16 hepatic T-cell lymphoma etanercept 10 mg biweekly × 0.1 years,
infliximab (10 mg/kg) monthly ×  1.7 years
11.8 9.9 from etanercept,
8.6 from infliximab
anakinraa (1.9),
cyclosporine A (0.9),
methotrexate (3.6),
tacrolimus (5.0), thalidomide (0.6),
etoposide (6 doses)
prednisone Unknown
F/Male Polyarteritis Nodosa (1.1 years) 14/19 lympho-proliferative disease (age 14);
renal clear cell carcinoma (age 19)
infliximab (100 mg) monthly ×  4.8 years 14.1 to lympho-proliferative disease;
18.6 to renal clear cell carcinoma
4.8 to lympho-proliferative disease;
9.3 to renal clear cell carcinoma
methotrexate (1.2), azathioprine (unknown),
cyclophosphamide (1.5)
prednisone, enalopril, amlodipine,
sulfamethoxazole, ranitidine, testosterone, protropin, nutropin, insulin, metformin, ferrous fumarate
Mother with breast cancer (deceased at age 31); Half-brother with suspected autoimmune lympho-proliferative disorder
Median (IQR) 3.4 (1.7–7.3) 16.3 (15.3–17.9) 5.0 (3.6–7.7) methotrexate: 5.4 (3.9–6.1)
  1. JIA = juvenile idiopathic arthritis
  2. aOther Biologic (non-anti-TNF)